Financial News
Immunic gets a "positive surprise" from lead asset trial
April 13, 2023 at 08:00 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).
Vitt describes it as "wonderful data" that came as a "positive surprise."
Contact Details
Proactive United States
Proactive United States
+1 347-449-0879
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
Institutional Money Is Pouring Into These 2 Altcoin ETFs ↗
Today 13:45 EDT
3 Dividend Kings to Buy While They’re Still Beaten Down ↗
Today 13:10 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
